Regeneron Pharmaceuticals Inc (REGN)

371.61
0.43 0.12
NASDAQ : Health Care
Prev Close 371.18
Open 372.18
Day Low/High 370.00 / 375.76
52 Wk Low/High 329.09 / 605.93
Volume 722.26K
Avg Volume 946.10K
Exchange NASDAQ
Shares Outstanding 106.08M
Market Cap 39.38B
EPS 6.20
P/E Ratio 48.21
Div & Yield N.A. (N.A)

Latest News

Chart of the Day: Amgen

There is more upside to come for this stock.

Bullish Momentum for Regeneron

Bullish Momentum for Regeneron

Volatility has calmed down, and there are bullish signs.

Chart of the Week: Regeneron

Volatility has calmed down, and there are bullish signs.

Analysts' Actions -- Evercore, Hasbro, J.C. Penney, Regeneron and More

Analysts' Actions -- Evercore, Hasbro, J.C. Penney, Regeneron and More

Here are Monday's top research calls, including upgrades for J.C. Penney and Regeneron, a downgrade for Evercore and new coverage of Hasbro.

Cramer: Here's the Reason for Allergan's Remarkable Run

Cramer: Here's the Reason for Allergan's Remarkable Run

Static doesn't work in this industry. Pipelines work.

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

Acorda was soaring ahead of the market open, thanks to positive late-stage clinical trial results for levodopa.

Cramer: Here's the Reason for Allergan's Remarkable Run

Cramer: Here's the Reason for Allergan's Remarkable Run

Static doesn't work in this industry. Pipelines work.

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Shares of late-stage biopharma Cytokinetics increased following positive comments from an Needham analyst.

Amgen Cholesterol-Lowering Drug Repatha Cuts Heart-Related Adverse Events in Big Study

Amgen Cholesterol-Lowering Drug Repatha Cuts Heart-Related Adverse Events in Big Study

The outcome of the so-called 'FOURIER' trial is extremely important for Amgen because the data will be used to lobby insurance companies to reimburse for Repatha.

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Biopharma's reticence suggests that fear of Trump's tweets and threats to limit drug pricing (and cut into profits) has stopped biotech companies from standing up for what's right.

Short Interest Decreases By 22.2% For REGN

Short Interest Decreases By 22.2% For REGN

The most recent short interest data has been released for the 01/13/2017 settlement date, which shows a 594,020 share decrease in total short interest for Regeneron Pharmaceuticals, Inc. , to 2,077,709, a decrease of 22.23% since 12/30/2016.

Forty Of Nation's Brightest Young Scientists Named Regeneron Science Talent Search 2017 Finalists

Forty Of Nation's Brightest Young Scientists Named Regeneron Science Talent Search 2017 Finalists

Finalists to Compete for Top Awards in Most Prestigious U.S. Science and Mathematics Competition for High School Seniors

Forty Of Nation's Brightest Young Scientists Named Regeneron Science Talent Search 2017 Finalists

Forty Of Nation's Brightest Young Scientists Named Regeneron Science Talent Search 2017 Finalists

Finalists to Compete for Top Awards in Most Prestigious U.S. Science and Mathematics Competition for High School Seniors

Regeneron Pharmaceuticals Could Be Ready to Rebound

Regeneron Pharmaceuticals Could Be Ready to Rebound

Regeneron has faced a lower stock price and patent wrangling. But the stock could be ready to rise again.

These Insiders Are Still Finding Some Good Value in the Stock Market

These Insiders Are Still Finding Some Good Value in the Stock Market

Look at what they are buying.

5 Rocket Stocks for 2017 -- Amgen, eBay, More

5 Rocket Stocks for 2017 -- Amgen, eBay, More

These stocks are showing short-term gain catalysts and longer-term growth potential. Here's how to trade them.

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Jim Cramer says he's focusing on health-care companies that will break news that moves stocks.

Closing Bell: Active Oil Rigs Rise; Dow Gets Close to 20K but Falls Short

Closing Bell: Active Oil Rigs Rise; Dow Gets Close to 20K but Falls Short

The Dow Jones Industrial Average came agonizingly close to its 20,000 milestone before falling short and backing off.

Dow Rises but Can't Reach 20,000 Milestone; S&P 500, Nasdaq Close at New Highs

Dow Rises but Can't Reach 20,000 Milestone; S&P 500, Nasdaq Close at New Highs

Dow 20,000 came agonizingly close on Friday, but building momentum flagged in the final moments of the trading session.

Dow Teases Wall Street With 20,000 Milestone but Backs Off

Dow Teases Wall Street With 20,000 Milestone but Backs Off

The Dow Jones Industrial Average backs away from its 20,000 milestone again on Friday after coming within a point of the level earlier in the session.

Here's Why Teva Shares Are Plummeting

Here's Why Teva Shares Are Plummeting

Shares fall on worse-than-expected guidance. It was not a good day for Teva Pharmaceuticals.

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.

Stocks Go Green as Wall Street Processes Slower Jobs Growth

Stocks Go Green as Wall Street Processes Slower Jobs Growth

Stocks rise Friday, though unsettled trading made gains uncertain, after wage growth in December raises the chances for a few rate hikes this year.

Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View

Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View

The Medicines Company, Alder also see share boosts on favorable implications. Jim Cramer weighs in on the implications for Amgen investors.

Use Regeneron's Current Weakness to Go Long

Use Regeneron's Current Weakness to Go Long

Usually I prefer to buy strength as opposed to buying weakness, but I want to depart from my normal behavior with this biotech.

Stock Futures Turn Higher After U.S. Adds 156,000 Jobs in December

Stock Futures Turn Higher After U.S. Adds 156,000 Jobs in December

Stock futures turn higher Friday after the Labor Department says the U.S. added 156,000 jobs in December.

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.